Missing link between metabolic syndrome and chronic kidney disease.?Role of asymmetric dimethylarginine-

代谢综合征（MetS）是慢性肾脏病（CKD）发生和发展的重要危险因素。一个可能的因素，可以解释这种联系似乎是内皮功能障碍（艾德）。在CKD患者中，ADMA水平与代谢因素和eGFR相关。此外，ADMA水平的增加与心血管疾病的替代标志物以及GFR的年下降率相关。MetS动物模型显示，DDAH（ADMA的一种酶）的失调可以解释ADMA升高，因此可能有助于Mets心血管疾病的发生和进展以及肾损伤。

Metabolic syndrome (MetS) is a strong risk factor for the initiation and development of chronic kidney disease (CKD). One possible factor that could explain this link seems to be endothelial dysfunction (ED). In CKD patients, ADMA levels were associated with metabolic factors and eGFR. Further, increased ADMA levels were associated with surrogate markers for cardiovascular disease as well as annual reduction rates of GFR. Animal models of MetS revealed that dysregulation of DDAH, an enzyme for ADMA could account for ADMA elevation, and therefore could contributed to the development and progression of cardiovascular disease as well as renal injury in Mets.